APO Research
Talk to an analyst

APO RESEARCH · REPORT

Influenza Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Influenza Drugs Market Outlook and Growth Opportunities 2026

20 December 2025208 pages

Choose your research edition.

Industry ResearchInfluenza Drugs Industry Research Report 2026133 pages · $2,950 USDIndustry Growth & TrendsGlobal Influenza Drugs Industry Growth and Trends Forecast to 2032113 pages · $3,450 USDMarket StructureGlobal Influenza Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Influenza Drugs Market Outlook and Growth Opportunities 2026208 pages · $4,250 USDMarket Analysis & ForecastGlobal Influenza Drugs Market Analysis and Forecast 2026-2032209 pages · $4,950 USD

Market perspective

The global Influenza Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Influenza Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Influenza Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Influenza Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Influenza Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Influenza Drugs market include Novartis, Roche, Eli Lilly, Pfizer, GlaxoSmithKline, Bayer, AstraZeneca, Serum Institute of India and Seqirus, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Influenza Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Influenza Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Influenza Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Influenza Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Influenza Drugs Segment by Company

Novartis

Roche

Eli Lilly

Pfizer

GlaxoSmithKline

Bayer

AstraZeneca

Serum Institute of India

Seqirus

Sanofi Pasteur

Protein Sciences Corporation

Emergent Biosolutions

Celgene

Bristol-Myers Squibb]

BioCryst Pharmaceuticals

Alvogen

Influenza Drugs Segment by Type

Oseltamivir Phosphate

Peramivir

Zanamivir

Other Influenza Drugs

Influenza Drugs Segment by Application

Adults

Chidren

Influenza Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Influenza Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Influenza Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Influenza Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Influenza Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Influenza Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Influenza Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Influenza Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Influenza Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Influenza Drugs industry.

Chapter 3: Detailed analysis of Influenza Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Influenza Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Influenza Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Influenza Drugs Industry Trends Table 2. Influenza Drugs Industry Drivers Table 3. Influenza Drugs Industry Opportunities and Challenges Table 4. Influenza Drugs Industry Restraints Table 5. Global Influenza Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Influenza Drugs Revenue Share by Company (2021-2026) Table 7. Global Influenza Drugs Sales Volume by Company (K Tons) & (2021-2026) Table 8. Global Influenza Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Influenza Drugs Average Price (US$/Ton) of Company (2021-2026) Table 10. Global Influenza Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Influenza Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Influenza Drugs Company, Product Type & Application Table 13. Global Influenza Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Influenza Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Oseltamivir Phosphate Table 18. Significant Companies of Peramivir Table 19. Significant Companies of Zanamivir Table 20. Significant Companies of Other Influenza Drugs Table 21. Global Influenza Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (K Tons) Table 22. Global Influenza Drugs Sales Volume by Type (2021-2026) & (K Tons) Table 23. Global Influenza Drugs Sales Volume by Type (2027-2032) & (K Tons) Table 24. Global Influenza Drugs Sales Volume Share by Type (2021-2026) Table 25. Global Influenza Drugs Sales Volume Share by Type (2027-2032) Table 26. Global Influenza Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Influenza Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Influenza Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Influenza Drugs Sales Value Share by Type (2021-2026) Table 30. Global Influenza Drugs Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Adults Table 32. Significant Companies of Chidren Table 33. Global Influenza Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (K Tons) Table 34. Global Influenza Drugs Sales Volume by Application (2021-2026) & (K Tons) Table 35. Global Influenza Drugs Sales Volume by Application (2027-2032) & (K Tons) Table 36. Global Influenza Drugs Sales Volume Share by Application (2021-2026) Table 37. Global Influenza Drugs Sales Volume Share by Application (2027-2032) Table 38. Global Influenza Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Influenza Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Influenza Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Influenza Drugs Sales Value Share by Application (2021-2026) Table 42. Global Influenza Drugs Sales Value Share by Application (2027-2032) Table 43. Global Influenza Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Tons) Table 44. Global Influenza Drugs Sales by Region (2021-2026) & (K Tons) Table 45. Global Influenza Drugs Sales Market Share by Region (2021-2026) Table 46. Global Influenza Drugs Sales by Region (2027-2032) & (K Tons) Table 47. Global Influenza Drugs Sales Market Share by Region (2027-2032) Table 48. Global Influenza Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Influenza Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Influenza Drugs Sales Value Share by Region (2021-2026) Table 51. Global Influenza Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Influenza Drugs Sales Value Share by Region (2027-2032) Table 53. Global Influenza Drugs Market Average Price (US$/Ton) by Region (2021-2026) Table 54. Global Influenza Drugs Market Average Price (US$/Ton) by Region (2027-2032) Table 55. Global Influenza Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Tons) Table 56. Global Influenza Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Influenza Drugs Sales by Country (2021-2026) & (K Tons) Table 58. Global Influenza Drugs Sales Market Share by Country (2021-2026) Table 59. Global Influenza Drugs Sales by Country (2027-2032) & (K Tons) Table 60. Global Influenza Drugs Sales Market Share by Country (2027-2032) Table 61. Global Influenza Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Influenza Drugs Sales Value Market Share by Country (2021-2026) Table 63. Global Influenza Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Influenza Drugs Sales Value Market Share by Country (2027-2032) Table 65. Novartis Company Information Table 66. Novartis Business Overview Table 67. Novartis Influenza Drugs Sales (K Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 68. Novartis Influenza Drugs Product Portfolio Table 69. Novartis Recent Development Table 70. Roche Company Information Table 71. Roche Business Overview Table 72. Roche Influenza Drugs Sales (K Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 73. Roche Influenza Drugs Product Portfolio Table 74. Roche Recent Development Table 75. Eli Lilly Company Information Table 76. Eli Lilly Business Overview Table 77. Eli Lilly Influenza Drugs Sales (K Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 78. Eli Lilly Influenza Drugs Product Portfolio Table 79. Eli Lilly Recent Development Table 80. Pfizer Company Information Table 81. Pfizer Business Overview Table 82. Pfizer Influenza Drugs Sales (K Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 83. Pfizer Influenza Drugs Product Portfolio Table 84. Pfizer Recent Development Table 85. GlaxoSmithKline Company Information Table 86. GlaxoSmithKline Business Overview Table 87. GlaxoSmithKline Influenza Drugs Sales (K Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 88. GlaxoSmithKline Influenza Drugs Product Portfolio Table 89. GlaxoSmithKline Recent Development Table 90. Bayer Company Information Table 91. Bayer Business Overview Table 92. Bayer Influenza Drugs Sales (K Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 93. Bayer Influenza Drugs Product Portfolio Table 94. Bayer Recent Development Table 95. AstraZeneca Company Information Table 96. AstraZeneca Business Overview Table 97. AstraZeneca Influenza Drugs Sales (K Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 98. AstraZeneca Influenza Drugs Product Portfolio Table 99. AstraZeneca Recent Development Table 100. Serum Institute of India Company Information Table 101. Serum Institute of India Business Overview Table 102. Serum Institute of India Influenza Drugs Sales (K Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 103. Serum Institute of India Influenza Drugs Product Portfolio Table 104. Serum Institute of India Recent Development Table 105. Seqirus Company Information Table 106. Seqirus Business Overview Table 107. Seqirus Influenza Drugs Sales (K Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 108. Seqirus Influenza Drugs Product Portfolio Table 109. Seqirus Recent Development Table 110. Sanofi Pasteur Company Information Table 111. Sanofi Pasteur Business Overview Table 112. Sanofi Pasteur Influenza Drugs Sales (K Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 113. Sanofi Pasteur Influenza Drugs Product Portfolio Table 114. Sanofi Pasteur Recent Development Table 115. Protein Sciences Corporation Company Information Table 116. Protein Sciences Corporation Business Overview Table 117. Protein Sciences Corporation Influenza Drugs Sales (K Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 118. Protein Sciences Corporation Influenza Drugs Product Portfolio Table 119. Protein Sciences Corporation Recent Development Table 120. Emergent Biosolutions Company Information Table 121. Emergent Biosolutions Business Overview Table 122. Emergent Biosolutions Influenza Drugs Sales (K Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 123. Emergent Biosolutions Influenza Drugs Product Portfolio Table 124. Emergent Biosolutions Recent Development Table 125. Celgene Company Information Table 126. Celgene Business Overview Table 127. Celgene Influenza Drugs Sales (K Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 128. Celgene Influenza Drugs Product Portfolio Table 129. Celgene Recent Development Table 130. Bristol-Myers Squibb] Company Information Table 131. Bristol-Myers Squibb] Business Overview Table 132. Bristol-Myers Squibb] Influenza Drugs Sales (K Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 133. Bristol-Myers Squibb] Influenza Drugs Product Portfolio Table 134. Bristol-Myers Squibb] Recent Development Table 135. BioCryst Pharmaceuticals Company Information Table 136. BioCryst Pharmaceuticals Business Overview Table 137. BioCryst Pharmaceuticals Influenza Drugs Sales (K Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 138. BioCryst Pharmaceuticals Influenza Drugs Product Portfolio Table 139. BioCryst Pharmaceuticals Recent Development Table 140. Alvogen Company Information Table 141. Alvogen Business Overview Table 142. Alvogen Influenza Drugs Sales (K Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 143. Alvogen Influenza Drugs Product Portfolio Table 144. Alvogen Recent Development Table 145. Key Raw Materials Table 146. Raw Materials Key Suppliers Table 147. Influenza Drugs Distributors List Table 148. Influenza Drugs Customers List Table 149. Research Programs/Design for This Report Table 150. Authors List of This Report Table 151. Secondary Sources Table 152. Primary Sources List of Figures Figure 1. Influenza Drugs Product Image Figure 2. Global Influenza Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Influenza Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Influenza Drugs Sales (2021-2032) & (K Tons) Figure 5. Global Influenza Drugs Sales Average Price (US$/Ton) & (2021-2032) Figure 6. Global Influenza Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Oseltamivir Phosphate Image Figure 10. Peramivir Image Figure 11. Zanamivir Image Figure 12. Other Influenza Drugs Image Figure 13. Global Influenza Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (K Tons) Figure 14. Global Influenza Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Influenza Drugs Sales Volume Share by Type (2021-2032) Figure 16. Global Influenza Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Influenza Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Influenza Drugs Sales Value Share by Type (2021-2032) Figure 19. Adults Image Figure 20. Chidren Image Figure 21. Global Influenza Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (K Tons) Figure 22. Global Influenza Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Influenza Drugs Sales Volume Share by Application (2021-2032) Figure 24. Global Influenza Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Influenza Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Influenza Drugs Sales Value Share by Application (2021-2032) Figure 27. Global Influenza Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Tons) Figure 28. Global Influenza Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Influenza Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Influenza Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Influenza Drugs Sales Value (2021-2032) & (US$ Million) Figure 32. North America Influenza Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Influenza Drugs Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Influenza Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Influenza Drugs Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Influenza Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Influenza Drugs Sales Value (2021-2032) & (US$ Million) Figure 38. South America Influenza Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Influenza Drugs Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Influenza Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Influenza Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Influenza Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Influenza Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Influenza Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Influenza Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Influenza Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Influenza Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Influenza Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Influenza Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Influenza Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Influenza Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Influenza Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Influenza Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Influenza Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Influenza Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Influenza Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Influenza Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Influenza Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Influenza Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Influenza Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Influenza Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Influenza Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Influenza Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Influenza Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Influenza Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Influenza Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Influenza Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Influenza Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Influenza Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Influenza Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Influenza Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Influenza Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Influenza Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Influenza Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Influenza Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Influenza Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Influenza Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Influenza Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Influenza Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Influenza Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Influenza Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Influenza Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Influenza Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Influenza Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Influenza Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Influenza Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Influenza Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Influenza Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Influenza Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Influenza Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Influenza Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Influenza Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Influenza Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Influenza Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Influenza Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Influenza Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Influenza Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Influenza Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Influenza Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Influenza Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Influenza Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Influenza Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Influenza Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Influenza Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Influenza Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Influenza Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Influenza Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Influenza Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Influenza Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Influenza Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Influenza Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Influenza Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Influenza Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Influenza Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Influenza Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Influenza Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Influenza Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Influenza Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Influenza Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Influenza Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Influenza Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Influenza Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Influenza Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Influenza Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Influenza Drugs Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Influenza Drugs Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Oseltamivir Phosphate
  • Peramivir
  • Zanamivir
  • Other Influenza Drugs
Applications
  • Adults
  • Chidren
Companies covered
  • Novartis
  • Roche
  • Eli Lilly
  • Pfizer
  • GlaxoSmithKline
  • Bayer
  • AstraZeneca
  • Serum Institute of India
  • Seqirus
  • Sanofi Pasteur
  • Protein Sciences Corporation
  • Emergent Biosolutions
  • Celgene
  • Bristol-Myers Squibb]
  • BioCryst Pharmaceuticals
  • Alvogen

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Influenza Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Influenza Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Influenza Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Influenza Drugs Market Dynamics
  1. 2.1 Influenza Drugs Industry Trends
  2. 2.2 Influenza Drugs Industry Drivers
  3. 2.3 Influenza Drugs Industry Opportunities and Challenges
  4. 2.4 Influenza Drugs Industry Restraints
3 Influenza Drugs Market by Company
  1. 3.1 Global Influenza Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Influenza Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Influenza Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Influenza Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Influenza Drugs Company Ranking (2024-2026)
  6. 3.6 Global Influenza Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Influenza Drugs Company Product Type and Application
  8. 3.8 Global Influenza Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Influenza Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Influenza Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Influenza Drugs Market by Type
  1. 4.1 Influenza Drugs Type Introduction
  2. 4.1.1 Oseltamivir Phosphate
  3. 4.1.2 Peramivir
  4. 4.1.3 Zanamivir
  5. 4.1.4 Other Influenza Drugs
  6. 4.2 Global Influenza Drugs Sales Volume by Type
  7. 4.2.1 Global Influenza Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Influenza Drugs Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Influenza Drugs Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Influenza Drugs Sales Value by Type
  11. 4.3.1 Global Influenza Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Influenza Drugs Sales Value by Type (2021-2032)
  13. 4.3.3 Global Influenza Drugs Sales Value Share by Type (2021-2032)
5 Influenza Drugs Market by Application
  1. 5.1 Influenza Drugs Application Introduction
  2. 5.1.1 Adults
  3. 5.1.2 Chidren
  4. 5.2 Global Influenza Drugs Sales Volume by Application
  5. 5.2.1 Global Influenza Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Influenza Drugs Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Influenza Drugs Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Influenza Drugs Sales Value by Application
  9. 5.3.1 Global Influenza Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Influenza Drugs Sales Value by Application (2021-2032)
  11. 5.3.3 Global Influenza Drugs Sales Value Share by Application (2021-2032)
6 Influenza Drugs Regional Sales and Value Analysis
  1. 6.1 Global Influenza Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Influenza Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Influenza Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Influenza Drugs Sales by Region (2027-2032)
  5. 6.3 Global Influenza Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Influenza Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Influenza Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Influenza Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Influenza Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Influenza Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Influenza Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Influenza Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Influenza Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Influenza Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Influenza Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Influenza Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Influenza Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Influenza Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Influenza Drugs Sales Value Share by Country, 2025 VS 2032
7 Influenza Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Influenza Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Influenza Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Influenza Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Influenza Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Influenza Drugs Sales by Country (2027-2032)
  6. 7.4 Global Influenza Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Influenza Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Influenza Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Influenza Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Influenza Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Influenza Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Influenza Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Influenza Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Influenza Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Influenza Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Influenza Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Influenza Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Influenza Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Influenza Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Influenza Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Influenza Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Influenza Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Influenza Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Influenza Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Influenza Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Influenza Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Influenza Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Influenza Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Influenza Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Influenza Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Influenza Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Influenza Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Influenza Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Influenza Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Influenza Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Influenza Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Influenza Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Influenza Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Influenza Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Influenza Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Influenza Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Influenza Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Influenza Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Influenza Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Influenza Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Influenza Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Influenza Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Influenza Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Influenza Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Influenza Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Influenza Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Influenza Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Influenza Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Influenza Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Influenza Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Influenza Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Influenza Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Influenza Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Influenza Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Influenza Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Influenza Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Influenza Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Influenza Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Influenza Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Influenza Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Influenza Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Influenza Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Influenza Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Influenza Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Influenza Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Influenza Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Influenza Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Influenza Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Influenza Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Influenza Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Influenza Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Influenza Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Influenza Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Influenza Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Influenza Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Influenza Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Influenza Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Influenza Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Influenza Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Influenza Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Influenza Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Influenza Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Influenza Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Influenza Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Influenza Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Influenza Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Influenza Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Novartis
  2. 8.1.1 Novartis Company Information
  3. 8.1.2 Novartis Business Overview
  4. 8.1.3 Novartis Influenza Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Novartis Influenza Drugs Product Portfolio
  6. 8.1.5 Novartis Recent Developments
  7. 8.2 Roche
  8. 8.2.1 Roche Company Information
  9. 8.2.2 Roche Business Overview
  10. 8.2.3 Roche Influenza Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Roche Influenza Drugs Product Portfolio
  12. 8.2.5 Roche Recent Developments
  13. 8.3 Eli Lilly
  14. 8.3.1 Eli Lilly Company Information
  15. 8.3.2 Eli Lilly Business Overview
  16. 8.3.3 Eli Lilly Influenza Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Eli Lilly Influenza Drugs Product Portfolio
  18. 8.3.5 Eli Lilly Recent Developments
  19. 8.4 Pfizer
  20. 8.4.1 Pfizer Company Information
  21. 8.4.2 Pfizer Business Overview
  22. 8.4.3 Pfizer Influenza Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Pfizer Influenza Drugs Product Portfolio
  24. 8.4.5 Pfizer Recent Developments
  25. 8.5 GlaxoSmithKline
  26. 8.5.1 GlaxoSmithKline Company Information
  27. 8.5.2 GlaxoSmithKline Business Overview
  28. 8.5.3 GlaxoSmithKline Influenza Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 GlaxoSmithKline Influenza Drugs Product Portfolio
  30. 8.5.5 GlaxoSmithKline Recent Developments
  31. 8.6 Bayer
  32. 8.6.1 Bayer Company Information
  33. 8.6.2 Bayer Business Overview
  34. 8.6.3 Bayer Influenza Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Bayer Influenza Drugs Product Portfolio
  36. 8.6.5 Bayer Recent Developments
  37. 8.7 AstraZeneca
  38. 8.7.1 AstraZeneca Company Information
  39. 8.7.2 AstraZeneca Business Overview
  40. 8.7.3 AstraZeneca Influenza Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 AstraZeneca Influenza Drugs Product Portfolio
  42. 8.7.5 AstraZeneca Recent Developments
  43. 8.8 Serum Institute of India
  44. 8.8.1 Serum Institute of India Company Information
  45. 8.8.2 Serum Institute of India Business Overview
  46. 8.8.3 Serum Institute of India Influenza Drugs Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Serum Institute of India Influenza Drugs Product Portfolio
  48. 8.8.5 Serum Institute of India Recent Developments
  49. 8.9 Seqirus
  50. 8.9.1 Seqirus Company Information
  51. 8.9.2 Seqirus Business Overview
  52. 8.9.3 Seqirus Influenza Drugs Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Seqirus Influenza Drugs Product Portfolio
  54. 8.9.5 Seqirus Recent Developments
  55. 8.10 Sanofi Pasteur
  56. 8.10.1 Sanofi Pasteur Company Information
  57. 8.10.2 Sanofi Pasteur Business Overview
  58. 8.10.3 Sanofi Pasteur Influenza Drugs Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Sanofi Pasteur Influenza Drugs Product Portfolio
  60. 8.10.5 Sanofi Pasteur Recent Developments
  61. 8.11 Protein Sciences Corporation
  62. 8.11.1 Protein Sciences Corporation Company Information
  63. 8.11.2 Protein Sciences Corporation Business Overview
  64. 8.11.3 Protein Sciences Corporation Influenza Drugs Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Protein Sciences Corporation Influenza Drugs Product Portfolio
  66. 8.11.5 Protein Sciences Corporation Recent Developments
  67. 8.12 Emergent Biosolutions
  68. 8.12.1 Emergent Biosolutions Company Information
  69. 8.12.2 Emergent Biosolutions Business Overview
  70. 8.12.3 Emergent Biosolutions Influenza Drugs Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Emergent Biosolutions Influenza Drugs Product Portfolio
  72. 8.12.5 Emergent Biosolutions Recent Developments
  73. 8.13 Celgene
  74. 8.13.1 Celgene Company Information
  75. 8.13.2 Celgene Business Overview
  76. 8.13.3 Celgene Influenza Drugs Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Celgene Influenza Drugs Product Portfolio
  78. 8.13.5 Celgene Recent Developments
  79. 8.14 Bristol-Myers Squibb]
  80. 8.14.1 Bristol-Myers Squibb] Company Information
  81. 8.14.2 Bristol-Myers Squibb] Business Overview
  82. 8.14.3 Bristol-Myers Squibb] Influenza Drugs Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Bristol-Myers Squibb] Influenza Drugs Product Portfolio
  84. 8.14.5 Bristol-Myers Squibb] Recent Developments
  85. 8.15 BioCryst Pharmaceuticals
  86. 8.15.1 BioCryst Pharmaceuticals Company Information
  87. 8.15.2 BioCryst Pharmaceuticals Business Overview
  88. 8.15.3 BioCryst Pharmaceuticals Influenza Drugs Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 BioCryst Pharmaceuticals Influenza Drugs Product Portfolio
  90. 8.15.5 BioCryst Pharmaceuticals Recent Developments
  91. 8.16 Alvogen
  92. 8.16.1 Alvogen Company Information
  93. 8.16.2 Alvogen Business Overview
  94. 8.16.3 Alvogen Influenza Drugs Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Alvogen Influenza Drugs Product Portfolio
  96. 8.16.5 Alvogen Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Influenza Drugs Value Chain Analysis
  2. 9.1.1 Influenza Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Influenza Drugs Sales Mode & Process
  6. 9.2 Influenza Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Influenza Drugs Distributors
  9. 9.2.3 Influenza Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst